SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Anton Neschadim, Alastair J.S. Summerlee, Joshua D. Silvertown, Targeting the relaxin hormonal pathway in prostate cancer, International Journal of Cancer, 2015, 136, 5
  2. 2
    MH Eileen Tan, Jun Li, H Eric Xu, Karsten Melcher, Eu-leong Yong, Androgen receptor: structure, role in prostate cancer and drug discovery, Acta Pharmacologica Sinica, 2014,

    CrossRef

  3. 3
    Mack Roach, Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer, Cancer, 2014, 120, 11
  4. 4
    Laurent Boccon-Gibod, Peter Albers, Juan Morote, Hendrik van Poppel, Jean de la Rosette, Arnauld Villers, Anders Malmberg, Anders Neijber, Francesco Montorsi, Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer, European Urology, 2014, 66, 4, 655

    CrossRef

  5. 5
    Laurence Klotz, Kurt Miller, E. David Crawford, Neal Shore, Bertrand Tombal, Cathrina Karup, Anders Malmberg, Bo-Eric Persson, Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists, European Urology, 2014, 66, 6, 1101

    CrossRef

  6. 6
    Yota Yasumizu, Akira Miyajima, Takeo Kosaka, Yasumasa Miyazaki, Eiji Kikuchi, Mototsugu Oya, Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer, The Journal of Urology, 2014, 191, 1, 227

    CrossRef

  7. 7
    Yasuo Sasagawa, Osamu Tachibana, Atsushi Nakagawa, Daisuke Koya, Hideaki Iizuka, Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma, Journal of Clinical Neuroscience, 2014,

    CrossRef

  8. 8
    Francesco Ricci, Giulia Buzzatti, Alessandra Rubagotti, Francesco Boccardo, Safety of antiandrogen therapy for treating prostate cancer, Expert Opinion on Drug Safety, 2014, 13, 11, 1483

    CrossRef

  9. 9
    Tsutomu Nishiyama, Serum testosterone levels after medical or surgical androgen deprivation: A comprehensive review of the literature, Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1, 38.e17

    CrossRef

  10. 10
    Ferenc G Rick, Norman L Block, Andrew V Schally, Agonists of luteinizing hormone-releasing hormone in prostate cancer, Expert Opinion on Pharmacotherapy, 2013, 14, 16, 2237

    CrossRef

  11. 11
    Patrizia Limonta, Marilena Manea, Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies, Cancer Treatment Reviews, 2013, 39, 6, 647

    CrossRef

  12. 12
    C. Bastide, F. Bruyère, G. Karsenty, L. Guy, F. Rozet, Le traitement hormonal du cancer de la prostate, Progrès en Urologie, 2013, 23, 15, 1246

    CrossRef

  13. 13
    Phillip L. Palmbos, Maha Hussain, Non-castrate Metastatic Prostate Cancer: Have the Treatment Options Changed?, Seminars in Oncology, 2013, 40, 3, 337

    CrossRef

  14. 14
    Jill A Trendel, The hurdle of antiandrogen drug resistance: drug design strategies, Expert Opinion on Drug Discovery, 2013, 8, 12, 1491

    CrossRef